A systematic review of randomised controlled trials of radiotherapy for localised prostate cancer

European Journal of Cancer

Volumn 51, Issue 16, 2015, Pages 2345-2367

  Wolff, Robert F ^a   Ryder, Steve ^a   Bossi, Alberto ^b   Briganti, Alberto ^c   Crook, Juanita ^d   Henry, Ann ^e   Karnes, Jeffrey ^f   Potters, Louis ^g   De Reijke, Theo ^h   Stone, Nelson ⁱ   Burckhardt, Marion ^j   Duffy, Steven ^a   Worthy, Gillian ^a   Kleijnen, Jos ^a,k  

^a KLEIJNEN SYSTEMATIC REVIEWS LTD   (United Kingdom)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^f MAYO CLINIC   (United States)

^g Northwell Health   (United States)

^h ACADEMIC MEDICAL CENTER   (Netherlands)

ⁱ Mount Sinai University   (United States)

^j MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^k MAASTRICHT UNIVERSITY   (Netherlands)

more..

Author keywords

Brachytherapy; Cryotherapy; High intensity focused ultrasound ablation; Prostatectomy; Prostatic neoplasms; Radiotherapy; Review; Watchful waiting

Indexed keywords

ARTICLE; BRACHYTHERAPY; CANCER HORMONE THERAPY; CRYOABLATION; CRYOTHERAPY; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL TOXICITY; GLEASON SCORE; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; LOCALIZED PROSTATE CANCER; OVERALL SURVIVAL; PATIENT SATISFACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SEXUAL FUNCTION; SYSTEMATIC REVIEW; UROGENITAL TRACT DISEASE; WATCHFUL WAITING; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADVERSE EFFECTS; CHEMORADIOTHERAPY; CHI SQUARE DISTRIBUTION; CRYOSURGERY; DISEASE COURSE; MALE; META ANALYSIS; MORTALITY; ODDS RATIO; PATHOLOGY; PROSTATIC NEOPLASMS; RADIATION DOSE; RISK FACTOR; SURVIVAL; TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ANTINEOPLASTIC AGENTS, HORMONAL; BRACHYTHERAPY; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; CRYOSURGERY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HIGH-INTENSITY FOCUSED ULTRASOUND ABLATION; HUMANS; MALE; ODDS RATIO; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; WATCHFUL WAITING;

EID: 84943665811     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.07.019     Document Type: Article

References (167)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2 2011 69 90
2. National Cancer Institute, and US National Institutes of Health SEER stat fact sheets: prostate cancer [Internet] 2014 National Cancer Institute Bethesda, MD [accessed 06.05.14]. Available from: http://seer.cancer.gov/statfacts/html/prost.html
3. D.M. Saman, A.M. Lemieux, M. Nawal Lutfiyya, and M.S. Lipsky A review of the current epidemiology and treatment options for prostate cancer Dis Mon 60 4 2014 150 154
4. A.S. Glass, J.E. Cowan, M.J. Fuldeore, M.R. Cooperberg, P.R. Carroll, S.A. Kenfield, and et al. Patient demographics, quality of life, and disease features of men with newly diagnosed prostate cancer: trends in the PSA era Urology 82 1 2013 60 65
5. A.B. Mariotto, K.R. Yabroff, Y. Shao, E.J. Feuer, and M.L. Brown Projections of the cost of cancer care in the United States: 2010-2020 J Natl Cancer Inst 103 2 2011 117 128
6. National Cancer Institute, and US National Institutes of Health Cancer trends progress report - 2011/2012 update: costs of cancer care [Internet] 2012 National Cancer Institute Bethesda, MD [accessed 06.05.14]. Available from: http://progressreport.cancer.gov/doc-detail.asp?pid=1&did=2007&chid=75&coid=726&
7. National Institute for Health and Care Excellence Prostate cancer: diagnosis and treatment. NICE clinical guideline 175 [Internet] 2014 National Institute for Health and Care Excellence London [accessed 24.10.14] Available from: http://guidance.nice.org.uk/CG175
8. M. Porta A dictionary of epidemiology 5th ed. 2008 Oxford University Press Oxford
9. J.P.T. Higgins, and S. Green Cochrane handbook for systematic reviews of interventions [Internet]. Version 5.1.0 [updated March 2011] 2011 The Cochrane Collaboration Available from: http://www.cochrane-handbook.org/
10. Centre for Reviews and Dissemination Systematic Reviews: CRD's guidance for undertaking reviews in health care [Internet] 2009 University of York York [cited 23.03.14] Available from: http://www.york.ac.uk/inst/crd/SysRev/!SSL!/WebHelp/SysRev3.htm
11. J.P. Higgins, D.G. Altman, P.C. Gotzsche, P. Juni, D. Moher, A.D. Oxman, and et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials BMJ 343 2011 d5928
12. A.V. D'Amico, R. Whittington, S.B. Malkowicz, K. Cote, M. Loffredo, D. Schultz, and et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era Cancer 95 2 2002 281 286
13. H.C. Bucher, G.H. Guyatt, L.E. Griffith, and S.D. Walter The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials J Clin Epidemiol 50 6 1997 683 691
14. J.M. Crook, A. Gomez-Iturriaga, K. Wallace, C. Ma, S. Fung, S. Alibhai, and et al. Comparison of health-related quality of life 5 years after spirit: surgical prostatectomy versus interstitial radiation intervention trial J Clin Oncol 29 4 2011 362 368
15. K. Wallace, N. Fleshner, M. Jewett, J. Basiuk, and J. Crook Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: the Toronto experience with the surgical prostatectomy versus interstitial radiation intervention trial J Clin Oncol 24 25 2006 4158 4162
16. J.M. Crook, A. Gomez-Iturriaga, K. Wallace, C. Ma, N. Fleshner, and M. Jewett Comparison of health-related quality of life 5 years after treatment for men who either chose or were randomized to radical prostatectomy or brachytherapy after a SPIRIT (ACOSOG Z0070) trial education session. Paper presented at 31st Annual Meeting of the American Brachytherapy Society; 29 Apr-1 May 2010; Atlanta: USA Brachytherapy 9 2010 S23
17. J. Crook Comparison of health-related quality of life 5 years after radical prostatectomy (RP) or brachytherapy (BT): the spirit (surgical prostatectomy versus interstitial radiotherapy intervention trial) cohort. Paper presented at Annual Scientific Meeting Research, Discovery, Collaboration and Education in Radiation Oncology and Physics; 22-25 Sep 2010; Vancouver: Canada Radiother Oncol 96 2010
18. J.M. Crook, A. Gomez-Iturriaga, K. Wallace, S. Fung, S. Alibhai, M. Jewett, and et al. Comparison of health-related quality of life 5 years after brachytherapy (BT) or radical prostatectomy (RP): the SPIRIT (surgical prostatectomy vs. interstitial radiotherapy intervention trial) cohort (ACOSOG Z0070). Paper presented at 52nd Annual Meeting of the American Society for Radiation Oncology; 31 Oct-04 Nov 2010; San Diego: USA Int J Radiat Oncol Biol Phys 78 3 Suppl. 1 2010 S76
19. C. Giberti, L. Chiono, F. Gallo, M. Schenone, and E. Gastaldi Radical retropubic prostatectomy versus brachytherapy for low-risk prostatic cancer: a prospective study World J Urol 27 5 2009 607 612
20. E.R. Cordeiro, X. Cathelineau, S. Thuroff, M. Marberger, S. Crouzet, and J.J. de la Rosette High-intensity focused ultrasound (HIFU) for definitive treatment of prostate cancer BJU Int 110 9 2012 1228 1242
21. I.J. Dahabreh, M. Chung, E.M. Balk, W.W. Yu, P. Mathew, J. Lau, and et al. Active surveillance in men with localized prostate cancer: A systematic review Ann Intern Med 156 8 2012 582 590
22. A.J. Stephenson, M. Bolla, A. Briganti, C. Cozzarini, J.W. Moul, M. Roach 3rd, and et al. Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy Eur Urol 61 3 2012 443 451
23. F. Peinemann, U. Grouven, C. Bartel, S. Sauerland, H. Borchers, M. Pinkawa, and et al. Permanent interstitial low-dose-rate brachytherapy for patients with localised prostate cancer: a systematic review of randomised and nonrandomised controlled clinical trials Eur Urol 60 5 2011 881 893
24. P. Grimm, I. Billiet, D. Bostwick, A.P. Dicker, S. Frank, J. Immerzeel, and et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group BJU Int 109 Suppl 1 2012 22 29
25. G. Rodrigues, P. Warde, T. Pickles, J. Crook, M. Brundage, L. Souhami, and et al. Pre-treatment risk stratification of prostate cancer patients: a critical review Can Urol Assoc J 6 2 2012 121 127
26. J. Mohler, R.R. Bahnson, B. Boston, J.E. Busby, A. D'Amico, J.A. Eastham, and et al. NCCN clinical practice guidelines in oncology: prostate cancer J Natl Compr Canc Netw 8 2 2010 162 200
27. R.A. Gardiner, J. Yaxley, G. Coughlin, N. Dunglison, S. Occhipinti, S. Younie, and et al. A randomised trial of robotic and open prostatectomy in men with localised prostate cancer BMC Cancer 12 2012 189
28. H. Konaka, S. Egawa, S. Saito, A. Yorozu, H. Takahashi, K. Miyakoda, and et al. Tri-Modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer (TRIP): study protocol for a phase III, multicenter, randomized, controlled trial BMC Cancer 12 2012 110
29. J.A. Lane, F.C. Hamdy, R.M. Martin, E.L. Turner, D.E. Neal, and J.L. Donovan Latest results from the UK trials evaluating prostate cancer screening and treatment: The CAP and ProtecT studies Eur J Cancer 46 17 2010 3095 3101
30. K. Miki, T. Kiba, H. Sasaki, M. Kido, M. Aoki, H. Takahashi, and et al. Transperineal prostate brachytherapy, using I-125 seed with or without adjuvant androgen deprivation, in patients with intermediate-risk prostate cancer: study protocol for a phase III, multicenter, randomized, controlled trial BMC Cancer 10 2010 572
31. K. Miki, K. Masahito, and M. Aoki Prostate brachytherapy with or without adjuvant ADT in intermediate prostate cancer: study protocol. Paper presented at ESTRO Anniversary - GEC-ESTRO - EIOF - 11th Biennial; 8-12 May 2011; London: United Kingdom Radiother Oncol 99 2011 S387 S388
32. B. van der Werf-Messing Prostatic cancer, stage III (C): a radiotherapeutic trial Jaarb Kankeronderz Kankerbestrijd Ned 23 1974 41 44
33. R.A. Gardiner, G.D. Coughlin, J.W. Yaxley, N.T. Dunglison, S. Occhipinti, S.J. Younie, and et al. A progress report on a prospective randomised trial of open and robotic prostatectomy Eur Urol 65 3 2014 512 515
34. O. Bratt, S. Carlsson, E. Holmberg, L. Holmberg, E. Johansson, A. Josefsson, and et al. The Study of Active Monitoring in Sweden (SAMS): a randomized study comparing two different follow-up schedules for active surveillance of low-risk prostate cancer Scand J Urol 47 5 2013 347 355
35. A. Nabid, N. Carrier, E. Vigneault, L. Souhami, C. Lemaire, M.A. Brassard, and et al. Testosterone variation in intermediate risk prostate cancer treated with androgen blockade and radiotherapy. Paper presented at Annual Conference of the European Society for Radiotherapy and Oncology; 9-13 May 2012; Barcelona: Spain Radiother Oncol 103 2012 S260 S261
36. F. Rozet, M. Habibian, J. Berille, L. Roca, L. Salomon, M. Soulie, and et al. A phase III randomized, open-label multicenter trial to evaluate the benefit of leuprorelin acetate for 24 months after radical prostatectomy in patients with high risk of recurrence (AFU-GETUG 20/0310). Paper presented at 2012 Genitourinary Cancers Symposium; 2-4 Feb 2012 J Clin Oncol 30 5 Suppl. 1 2012 252
37. A. Tree, S. Aluwini, H. Bryant, E. Hall, L. Incrocci, I. Kaplan, and et al. Successful patient acceptance of randomization within the PACE study (Prostate Advances in Comparative Evidence). Paper presented at 55th Annual Meeting of the American Society for Radiation Oncology (ASTRO); 22-25 Sep 2013; Atlanta: USA Int J Radiat Oncol Biol Phys 87 2 Suppl 1 2013 S365
38. PREFERE PREFERE: die deutsche Prostatakrebs-Studie [Internet] 2013 Deutsche Krebshilfe Bonn [accessed 09.09.13]. Available from: http://www.prefere.de/
39. T. Wiegel, P. Albers, R. Bussar-Maatz, A. Gottberg, M. Harter, M. Kieser, and et al. PREFERE - the German prostatic cancer study: questions and claims surrounding study initiation in January 2013 Urol A 52 4 2013 576 579
40. School of Social and Community Medicine, and University of Bristol The ProtecT trial - Evaluating the effectiveness of treatment for clinically localised prostate cancer. ISRCTN20141297 ISRCTN Registry [Internet] 2002 Springer [accessed 9.3.13]. Available from: http://www.isrctn.com/ISRCTN20141297
41. X. Cui, Q. Li, J.J. Xu, J. Li, and T.W. Ou Application of neoadjuvant hormonal therapy in (125)I permanent seed implantation for prostate cancer Zhonghua Yi Xue Za Zhi 92 38 2012 2710 2712
42. A. Al-Zahrani, A.M. Autran, A. Williams, G. Bauman, J. Izawa, and J. Chin Long-term outcome of randomized trial between cryoablation and external beam therapy for locally advanced prostate cancer (T2c-T3b). Paper presented at Annual Meeting of the American Urological Association; 14-19 May 2011; Washington, DC: USA J Urol 185 4 Suppl. 1 2011 e258
43. A. Al-Zahrani, V. Yutkin, A. Autran, J. Izawa, and J. Chin Long-term outcome of randomized trial between cryoablation and external beam therapy for locally advanced prostate cancer (T2c-T3b). Paper presented at 32nd Congress of the Societe Internationale d'Urologie; 30 Sep-4 Oct 2012; Fukuoka: Japan Urology 80 3 Suppl. 1 2012 S271
44. A.A. Al-Zahrani, A.M. Autran, A. Williams, G. Bauman, and J.L. Chin Long-term outcome of randomized trial between cryoablation and external beam therapy for locally advanced prostate cancer (T2c-T3b). Paper presented at 26th Annual Congress of the European Association of Urology; 18-22 Mar 2011; Vienna: Austria Eur Urol 10 2 2011 52
45. A.A. Al-Zahrani, A. Autran Gomez, A. Williams, G. Bauman, J. Izawa, and J. Chin Long-term outcome of randomized trial between cryoablation and external beam therapy for locally advanced prostate cancer (T2C-T3B) J Clin Oncol 29 7 Suppl 1 2011
46. B.J. Donnelly, J.C. Saliken, P.M.A. Brasher, S.D. Ernst, J.C. Rewcastle, H. Lau, and et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer Cancer 116 2 2010 323 330
47. J.W. Robinson, B.J. Donnelly, J.E. Siever, J.C. Saliken, S.D. Ernst, J.C. Rewcastle, and et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer: quality of life outcomes Cancer 115 20 2009 4695 4704
48. P.J. Hoskin, A.M. Rojas, P.J. Bownes, G.J. Lowe, P.J. Ostler, and L. Bryant Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer Radiother Oncol 103 2 2012 217 222
49. P.J. Hoskin, K. Motohashi, P. Bownes, L. Bryant, and P. Ostler High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial Radiother Oncol 84 2 2007 114 120
50. P. Hoskin, A. Rojas, P. Ostler, R. Hughes, L. Bryant, G. Lowe, and et al. Quality of Life after radical radiotherapy for prostate cancer: results from a randomised trial of EBRT+/- HDR-BT. Paper presented at Annual Conference of the European Society for Radiotherapy and Oncology; 9-13 May 2012; Barcelona: Spain Radiother Oncol 103 2012 S20
51. P. Hoskin, A.M. Rojas, P.J. Ostler, R. Hughes, L. Bryant, G. Lowe, and et al. Randomised trial of external beam radiotherapy alone or with high-dose-rate brachytherapy boost in localised prostate cancer. Paper presented at European Society for Therapeutic Radiology and Oncology; 12-16 Sep 2010; Barcelona: Spain Radiother Oncol 96 2010 S112 S113
52. P.J. Hoskin, A.M. Rojas, P.J. Ostler, R. Hughes, G.J. Lowe, and L. Bryant Quality of life after radical radiotherapy for prostate cancer: longitudinal study from a randomised trial of external beam radiotherapy alone or in combination with high dose rate brachytherapy Clin Oncol 25 5 2013 321 327
53. J.R. Sathya, I.R. Davis, J.A. Julian, Q. Guo, D. Daya, I.S. Dayes, and et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate J Clin Oncol 23 6 2005 1192 1199
54. J. Zapatero Ortuno, P.M. Samper Ots, M.C. Lopez Carrizosa, A. Rodriguez Perez, J.D.D. Saez Garrido, M. Lopez Gonzalez, and et al. Intermediate risk localized prostate cancer treated with three-dimensional conformal RT (3DCR) versus 3DCR with low dose rate brachytherapy boost (3DCR+BT). Paper presented at European Society for Therapeutic Radiology and Oncology; 12-16 Sep 2010; Barcelona: Spain Radiother Oncol 96 2010 S216
55. M. Bolla, G. van Tienhoven, P. Warde, J.B. Dubois, R.-O. Mirimanoff, G. Storme, and et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study Lancet Oncol 11 11 2010 1066 1073
56. M. Bolla, L. Collette, L. Blank, P. Warde, J.B. Dubois, R.O. Mirimanoff, and et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial Lancet 360 9327 2002 103 108
57. M. Bolla, L. Collette, G. van Tienhoven, P. Warde, J.B. Dubois, R.O. Mirimanoff, and et al. Three years of adjuvant androgen deprivation with goserelin in patients with locally advanced prostate cancer treated with radiotherapy: results at 10 years of EORTC trial 22863. Paper presented at Joint ECCO 15-34th ESMO Multidisciplinary Congress; 20-24 Sep 2009; Berlin: Germany EJC Suppl 7 2-3 2009 408
58. M. Bolla, D. Gonzalez, P. Warde, J.B. Dubois, R.O. Mirimanoff, G. Storme, and et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin N Engl J Med 337 5 1997 295 300
59. M. Bolla, L. Collette, D. Gonzales, P. Warde, J.B. Dubois, R. Mirimanoff, and et al. Long term results of immediate adjuvant hormonal therapy with goserelin in patients with locally advanced prostate cancer treated with radiotherapy: a phase III EORTC study. Paper presented at 41st meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO); 31 Oct-4 Nov 1999; San Antonio: USA Int J Radiat Oncol Biol Phys 45 3 Suppl 1999 147
60. A.V. D'Amico, J. Manola, M. Loffredo, A.A. Renshaw, A. DellaCroce, and P.W. Kantoff 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial JAMA 292 7 2004 821 827
61. P.L. Nguyen, M.-H. Chen, A.A. Renshaw, M. Loffredo, P.W. Kantoff, and A.V. D'Amico Survival following radiation and androgen suppression therapy for prostate cancer in healthy older men: implications for screening recommendations Int J Radiat Oncol Biol Phys 76 2 2010 337 341
62. A.V. D'Amico, M.-H. Chen, A.A. Renshaw, M. Loffredo, and P.W. Kantoff Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial JAMA 299 3 2008 289 295
63. J. Denham, A. Steigler, D. Lamb, O. Joseph, S. Turner, J. Matthews, and et al. 10 year main endpoints data from the TROG 9601 trial. Paper presented at European Society for Therapeutic Radiology and Oncology; 12-16 Sep 2010; Barcelona: Spain Radiother Oncol 96 2010 S147
64. J. Denham, A. Steigler, D. Lamb, D. Joseph, S. Turner, J. Matthews, and et al. Important mortality reductions by short term androgen deprivation and radiotherapy for locally advanced prostate cancer: 10 year trial data from TROG 96.01. Paper presented at ESTRO Anniversary Congress; 8-12 May 2011; London: United Kingdom Radiother Oncol 2011 99 May 2011 S200 201
65. J.W. Denham, M. Kumar, P.S. Gleeson, D.S. Lamb, D. Joseph, C. Atkinson, and et al. Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer Int J Radiat Oncol Biol Phys 74 2 2009 404 411
66. J.W. Denham, A. Steigler, D.S. Lamb, D. Joseph, S. Turner, J. Matthews, and et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial Lancet Oncol 12 5 2011 451 459
67. J.W. Denham, A. Steigler, C. Wilcox, D.S. Lamb, D. Joseph, C. Atkinson, and et al. Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial Lancet Oncol 9 11 2008 1058 1068
68. C.U. Jones, D. Hunt, D.G. McGowan, M.B. Amin, M.P. Chetner, D.W. Bruner, and et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer N Engl J Med 365 2 2011 107 118
69. J.A. Efstathiou, R. Paulus, M.R. Smith, C.U. Jones, M.H. Leibenhaut, S.M. Husain, and et al. Cardiovascular mortality following short-term androgen deprivation in clinically localized prostate cancer: an analysis of RTOG 94-08. Paper presented at 53rd Annual Meeting of the American Society for Radiation Oncology; 2-6 Oct 2011; Miami Beach: USA Int J Radiat Oncol Biol Phys 81 2 Suppl 1 2011 S41
70. M. Roach, D. Hunt, C.U. Jones, J. Bahary, K.L. Zeitzer, L. Souhami, and et al. Radiation Therapy Oncology Group (RTOG) 9408: a secondary analysis of the risk of death from second cancers comparing whole pelvic (WP) radiation therapy (RT) to prostate only (PO) RT and neoadjuvant hormonal therapy (NHT) + RT to RT alone. Paper presented at 55th Annual Meeting of the American Society for Radiation Oncology (ASTRO); 22-25 Sep 2013; Atlanta: USA Int J Radiat Oncol Biol Phys 87 2 Suppl. 1 2013 S357
71. D.J. Krauss, D. Hunt, J. Bahary, L. Souhami, E. Gore, S. Chafe, and et al. Inferior clinical outcomes for patients with positive post-radiation therapy prostate biopsy: results from prospective randomized trial RTOG 94-08. Paper presented at 55th Annual Meeting of the American Society for Radiation Oncology (ASTRO); 22-25 Sep 2013; Atlanta: USA Int J Radiat Oncol Biol Phys 87 2 Suppl. 1 2013 S23
72. J.A. Efstathiou, R. Paulus, M.R. Smith, C.U. Jones, M.H. Leibenhaut, S.M. Husain, and et al. Cardiovascular mortality following short-term androgen deprivation in clinically localized prostate cancer: an analysis of RTOG 94-08. Paper presented at 2012 Genitourinary Cancers Symposium; 2-4 Feb 2012; San Francisco: USA J Clin Oncol 30 5 Suppl. 1 2012 18
73. J. Laverdiere, J.L. Gomez, L. Cusan, E.R. Suburu, P. Diamond, M. Lemay, and et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer Int J Radiat Oncol Biol Phys 37 2 1997 247 252
74. M.V. Pilepich, W.T. Sause, W.U. Shipley, J.M. Krall, C.A. Lawton, D. Grignon, and et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group Urology 45 4 1995 616 623
75. M.V. Pilepich, K. Winter, M.J. John, J.B. Mesic, W. Sause, P. Rubin, and et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate Int J Radiat Oncol Biol Phys 50 5 2001 1243 1252
76. M. Zhang, A. Ho, E.H. Hammond, Y. Suzuki, R.S. Bermudez, R.J. Lee, and et al. Prognostic value of survivin in locally advanced prostate cancer: study based on RTOG 8610 Int J Radiat Oncol Biol Phys 73 4 2009 1033 1042
77. M. Roach 3rd, K. Bae, J. Speight, H.B. Wolkov, P. Rubin, R.J. Lee, and et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610 J Clin Oncol 26 4 2008 585 591
78. M. Abdel-Wahab, B.A. Berkey, A. Krishan, T. O'Brien, E. Hammond, M. Roach 3rd, and et al. Influence of number of CAG repeats on local control in the RTOG 86-10 protocol Am J Clin Oncol 29 1 2006 14 20
79. G.K. Zagars, D.E. Johnson, A.C. von Eschenbach, and D.H. Hussey Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study Int J Radiat Oncol Biol Phys 14 6 1988 1085 1091
80. W.J. Neglia, D.H. Hussey, and D.E. Johnson Megavoltage radiation therapy for carcinoma of the prostate Int J Radiat Oncol Biol Phys 2 9-10 1977 873 883
81. G. Spagnoletti, R. Marchese, R. Rignanese, A.M. Leo, V. Verile, G. Plotino, and et al. Hypofractionation versus conventionally fractionated radiation therapy for prostate cancer: late toxicity. Paper presented at 21st Annual Meeting of the Italian Society of Uro-Oncology; 22-24 Jun 2011; Naples: Italy Anticancer Res 31 5 2011 1887 1888
82. G. Spagnoletti, R. Rignanese, V. Verile, G. Plotino, V. Oriolo, and G. Bove Hypofractionation versus conventionally fractionated radiation therapy for prostate cancer: our first results. Paper presented at 20th Annual Meeting of the Italian Society of Uro-Oncology; 23-25 Jun 2010; Rome: Italy Anticancer Res 30 4 2010 1472 1473
83. G. Mok, R. Glicksman, J. Sykes, A. Bayley, P. Chung, R. Bristrow, and et al. Short term hormone therapy and dose escalated radiation for localized prostate cancer: a randomized phase III study. Paper presented at Annual Conference of the European Society for Radiotherapy and Oncology; 9-13 May 2012; Barcelona: Spain Radiother Oncol 103 2012 S18
84. D. Norkus, A. Karklelyte, B. Engels, H. Versmessen, R. Griskevicius, M. De Ridder, and et al. A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: interim analysis of acute toxicity and quality of life in 124 patients Radiat Oncol 8 1 2013 206
85. S. Aluwini, F. Pos, E. van Lin, E. Schimmel, A. Krol, P. van der Toorn, and et al. Acute toxicity of the randomized phase III Dutch hypofractionation trial (hypro) for prostate cancer. Paper presented at Annual Conference of the European Society for Radiotherapy and Oncology; 9-13 May 2012; Barcelona: Spain Radiother Oncol 103 2012 S84 S85
86. S. Arcangeli, L. Strigari, S. Gomellini, B. Saracino, M.G. Petrongari, P. Pinnaro, and et al. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer Int J Radiat Oncol Biol Phys 84 5 2012 1172 1178
87. G. Arcangeli, J. Fowler, S. Gomellini, S. Arcangeli, B. Saracino, M.G. Petrongari, and et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 79 4 2011 1013 1021
88. G. Arcangeli, B. Saracino, S. Gomellini, M.G. Petrongari, S. Arcangeli, S. Sentinelli, and et al. A Prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer Int J Radiat Oncol Biol Phys 78 1 2010 11 18
89. L. Strigari, G. Arcangeli, S. Arcangeli, and M. Benassi Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer Int J Radiat Oncol Biol Phys 73 5 2009 1454 1460
90. S. Arcangeli, L. Strigari, S. Gomellini, B. Saracino, M. Petrongari, P. Pinnaro, and et al. Updated results and pattern of failure in a randomized hypofractionation trial for high-risk prostate cancer. Paper presented at 54th Annual Meeting of the American Society for Radiation Oncology; 28-31 Oct 2012; Boston: USA Int J Radiat Oncol Biol Phys 84 3 2012 S147
91. G. Arcangeli, S. Arcangeli, B.M. Saracino, M.G. Petronqari, S. Gomellini, L. Striqari, and et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Paper presented at European Society for Therapeutic Radiology and Oncology; 12-16 Sep 2010; Barcelona: Spain Radiother Oncol 96 2010 S147
92. S. Marzi, B. Saracino, M.G. Petrongari, S. Arcangeli, S. Gomellini, G. Arcangeli, and et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer J Exp Clin Cancer Res 28 2009 117
93. V. Beckendorf, S. Guerif, E. Le Prise, J.-M. Cosset, A. Bougnoux, B. Chauvet, and et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial Int J Radiat Oncol Biol Phys 80 4 2011 1056 1063
94. V. Beckendorf, S. Guerif, E. Le Prise, J.M. Cosset, O. Lefloch, B. Chauvet, and et al. The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity Int J Radiat Oncol Biol Phys 60 4 2004 1056 1065
95. V. Beckendorf, S. Guerif, E. Le Prise, J.M. Cosset, O. Lefloch, B. Chauvet, and et al. The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity Urol Oncol 23 4 2005 307
96. S.T.H. Peeters, W.D. Heemsbergen, P.C.M. Koper, W.L.J. van Putten, A. Slot, M.F.H. Dielwart, and et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy J Clin Oncol 24 13 2006 1990 1996
97. S.T.H. Peeters, W.D. Heemsbergen, W.L.J. van Putten, A. Slot, H. Tabak, J.W. Mens, and et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy Int J Radiat Oncol Biol Phys 61 4 2005 1019 1034
98. W.D. Heemsbergen, A. Al-Mamgani, M.G. Witte, M. van Herk, F.J. Pos, and J.V. Lebesque Urinary obstruction in prostate cancer patients from the dutch trial (68 Gy vs. 78 Gy): relationships with local dose acute effects and baseline characteristics Int J Radiat Oncol Biol Phys 78 1 2010 19 25
99. A. Al-Mamgani, W.L.J. van Putten, W.D. Heemsbergen, G.J.L.H. van Leenders, A. Slot, M.F.H. Dielwart, and et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer Int J Radiat Oncol Biol Phys 72 4 2008 980 988
100. A. Al-Mamgani, W.D. Heemsbergen, S.T.H. Peeters, and J.V. Lebesque Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer Int J Radiat Oncol Biol Phys 73 3 2009 685 691
101. A. Al-Mamgani, W.L.J. van Putten, G.J. van Der Wielen, P.C. Levendag, and L. Incrocci Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the dutch randomized dose-escalation trial (CKTO 96-10 Trial) Int J Radiat Oncol Biol Phys 79 4 2011 1004 1012
102. S.T.H. Peeters, M.S. Hoogeman, W.D. Heemsbergen, A. Slot, H. Tabak, P.C.M. Koper, and et al. Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 63 4 2005 1142 1152
103. G.J. van der Wielen, W.L.J. van Putten, and L. Incrocci Sexual function after three-dimensional conformal radiotherapy for prostate cancer: results from a dose-escalation trial Int J Radiat Oncol Biol Phys 68 2 2007 479 484
104. W.D. Heemsbergen, A. Al-Mamgani, A. Slot, M.F. Dielwart, and J.V. Lebesque Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival Radiother Oncol 110 1 2014 104 109
105. D.A. Kuban, S.L. Tucker, L. Dong, G. Starkschall, E.H. Huang, M.R. Cheung, and et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer Int J Radiat Oncol Biol Phys 70 1 2008 67 74
106. D. Kuban, A. Pollack, E. Huang, L. Levy, L. Dong, G. Starkschall, and et al. Hazards of dose escalation in prostate cancer radiotherapy Int J Radiat Oncol Biol Phys 57 5 2003 1260 1268
107. D.J. Little, D.A. Kuban, L.B. Levy, G.K. Zagars, and A. Pollack Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study Urology 62 4 2003 707 713
108. A. Pollack, G.K. Zagars, L.G. Smith, J.J. Lee, A.C. Von Eschenbach, J.A. Antolak, and et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer J Clin Oncol 18 23 2000 3904 3911
109. A. Pollack, G.K. Zagars, G. Starkschall, J.A. Antolak, J.J. Lee, E. Huang, and et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial Int J Radiat Oncol Biol Phys 53 5 2002 1097 1105
110. M.R. Storey, A. Pollack, G. Zagars, L. Smith, J. Antolak, and I. Rosen Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial Int J Radiat Oncol Biol Phys 48 3 2000 635 642
111. L.N. Nguyen, A. Pollack, and G.K. Zagars Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire Urology 51 6 1998 991 997
112. A. Pollack, G.K. Zagars, G. Starkschall, C.H. Childress, S. Kopplin, A.L. Boyer, and et al. Conventional vs. conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity Int J Radiat Oncol Biol Phys 34 3 1996 555 564
113. A. Pollack, G.K. Zagars, L.G. Smith, and J.A. Antolak Preliminary results of a randomized dose-escalation study comparing 70 Gy to 78 Gy for the treatment of prostate cancer. Paper presented at 41st meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO); 31 Oct-4 Nov 1999; San Antonio: USA Int J Radiat Oncol Biol Phys 45 3 1999 146 147
114. P.L. Nguyen, R.C. Chen, K.E. Hoffman, A. Trofimov, J.A. Efstathiou, J.J. Coen, and et al. Rectal dose-volume histogram parameters are associated with long-term patient-reported gastrointestinal quality of life after conventional and high-dose radiation for prostate cancer: a subgroup analysis of a randomized trial Int J Radiat Oncol Biol Phys 78 4 2010 1081 1085
115. W.U. Shipley Update on PROG 95-09: 10 year outcomes of 79 Gy versus 70 Gy conformal RT in low- and intermediate-risk prostate cancer. Paper presented at European Society for Therapeutic Radiology and Oncology; 12-16 Sep 2010; Barcelona: Spain Radiother Oncol 96 2010 S37
116. A.L. Zietman, K. Bae, J.D. Slater, W.U. Shipley, J.A. Efstathiou, J.J. Coen, and et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09 J Clin Oncol 28 7 2010 1106 1111
117. A.L. Zietman, M.L. DeSilvio, J.D. Slater, C.J. Rossi Jr., D.W. Miller, J.A. Adams, and et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. [Erratum appears in JAMA 2008 Feb 27;299(8):899-900] JAMA 294 10 2005 1233 1239
118. D.F. Paulson Management of patients with prostatic adenocarcinoma Aktuelle Urologie 13 2 1982 91 95
119. D.F. Paulson, G.H. Lin, W. Hinshaw, and S. Stephani Radical surgery versus radiotherapy for adenocarcinoma of the prostate J Urol 128 3 1982 502 504
120. P. Fransson, J.-E. Damber, and A. Widmark Health-related quality of life 10 years after external beam radiotherapy or watchful waiting in patients with localized prostate cancer Scand J Urol Nephrol 43 2 2009 119 126
121. P. Fransson, J.E. Damber, R. Tomic, H. Modig, G. Nyberg, and A. Widmark Quality of life and symptoms in a randomized trial of radiotherapy versus deferred treatment of localized prostate carcinoma Cancer 92 12 2001 3111 3119
122. P. Fransson, J.E. Dauber, R. Tomic, H. Modig, and A. Widmark A randomized trial of radiotherapy versus deferred treatment in localized prostate cancer patients: evaluation of urinary and intestinal symptoms Int J Radiat Oncol Biol Phys 45 3 Suppl. 1999 352
123. A.T. Porter, M. Elhilali, M. Manji, D. Grignon, G. Thomas, G.E. Kostashuk, and et al. A phase III randomized trial to evaluate the efficacy of neoadjuvant therapy prior to curative radiotherapy in locally advanced prostate cancer patients: a Canadian Urologic Oncology Group study Proc Am Soc Clin Oncol 16 1997 315a
124. S.M. Stasi, A. Giannantoni, M. Valenti, L. Storti, F. Attisani, T. Palloni, and et al. Multicenter, randomized, phase III trial comparing radical retropubic prostatectomy with conventional external beam radiotherapy for localized prostate cancer: an interim report J Clin Oncol 24 18S 2006 4607
125. A. Garcia Blanco, J. Anchuelo Latorre, G. Paya Barcela, J. Cardenal Carro, E. Acuna Rubio, and J. Vazquez Rodriguez Brachytherapy in localized prostate cancer with or without androgen deprivation. Paper presented at 17th Meeting of the Radiation Oncology Spanish Society (SEOR); 18-21 Jun 2013; Vigo: Spain Rep Pract Oncol Radiother 18 Suppl. 1 2013 S142
126. M. Bolla, H. van Poppel, B. Tombal, K. Vekemans, L. Da Pozzo, T.M. de Reijke, and et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911) Lancet 380 9858 2012 2018 2027
127. M. Bolla, H. van Poppel, B. Tombal, K. Vekemans, L.F. Da Pozzo, and T. de Reijke Long term results of immediate postoperative radiotherapy after radical prostatectomy in PT3N0 prostate cancer (EORTC 22911). Paper presented at European Society for Therapeutic Radiology and Oncology; 12-16 Sep 2010; Barcelona: Spain Radiother Oncol 96 2010 S113
128. M. Bolla, H. van Poppel, B. Tombal, K. Vekemans, L. Da Pozzo, T.M. de Reijke, and et al. 10-Year results of adjuvant radiotherapy after radical prostatectomy in PT3N0 prostate cancer (EORTC 22911). Paper presented at 52nd Annual Meeting of the American Society for Radiation Oncology; 31 Oct-04 Nov 2010; San Diego, USA Int J Radiat Oncol Biol Phys 78 3 Suppl. 1 2010 S29
129. M. Bolla, H. van Poppel, and L. Collette Preliminary results for EORTC trial 22911: radical prostatectomy followed by postoperative radiotherapy in prostate cancers with a high risk of progression Cancer Radiother 11 6-7 2007 363 369
130. T.H. van der Kwast, M. Bolla, H. van Poppel, P. van Cangh, K. Vekemans, L. Da Pozzo, and et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911 J Clin Oncol 25 27 2007 4178 4186
131. M. Bolla, H. van Poppel, L. Collette, P. van Cangh, K. Vekemans, L. Da Pozzo, and et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911) Lancet 366 9485 2005 572 578
132. O. Matzinger, F. Duclos, A. van den Bergh, C. Carrie, S. Villa, P. Kitsios, and et al. Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991 Eur J Cancer 45 16 2009 2825 2834
133. O. Matzinger, F. Duclos, A. van den Bergh, C. Carrie, P. Kitsios, S. Villa, and et al. Acute toxicity of curative radiotherapy for intermediate risk localized prostate cancer in the EORTC trial 22991. Paper presented at Joint ECCO 15-34th ESMO Multidisciplinary Congress; 20-24 Sep 2009; Berlin: Germany EJC Suppl 7 2-3 2009 151 152
134. G.P. Swanson, B. Goldman, C.M. Tangen, J. Chin, E. Messing, E. Canby-Hagino, and et al. The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794 J Urol 180 6 2008 2453 2457
135. G.P. Swanson, M.A. Hussey, C.M. Tangen, J. Chin, E. Messing, E. Canby-Hagino, and et al. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794 J Clin Oncol 25 16 2007 2225 2229
136. I.M. Thompson Jr., C.M. Tangen, J. Paradelo, M.S. Lucia, G. Miller, D. Troyer, and et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial JAMA 296 19 2006 2329 2335
137. I.M. Thompson, C.M. Tangen, J. Paradelo, M.S. Lucia, G. Miller, D. Troyer, and et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial J Urol 181 3 2009 956 962
138. T. Wiegel, D. Bottke, U. Steiner, A. Siegmann, R. Golz, S. Storkel, and et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95 J Clin Oncol 27 18 2009 2924 2930
139. D. Bottke, S. Storkel, R. Golz, A. Siegmann, N. Willich, L. Hertel, and et al. Phase III study of adjuvant RT for prostate cancer: impact of pathologic review on analysis. Paper presented at Annual Conference of the European Society for Radiotherapy and Oncology; 9-13. Barcelona: Spain Radiother Oncol 103 2012 S18
140. T. Wiegel, D. Bottke, N. Willich, H.-J. Piechota, R. Souchon, M. Stoecke, and et al. Phase III results of adjuvant radiotherapy (RT) versus, wait and see" (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP)(ARO 96-02/AUO AP 09/95) Proc Am Soc Clin Oncol 23 2005 381
141. T. Wiegel, D. Bottke, D. Bartkowiak, C. Bronner, U. Steiner, A. Siegmann, and et al. Phase III results of adjuvant radiotherapy (RT) versus wait-and-see (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP)(ARO 96-02/AUO AP 09/95): ten years follow-up. Paper presented at 2013 Genitourinary Cancers Symposium; 14-16 Feb 2013; Orlando: USA J Clin Oncol 31 6 Suppl. 1 2013 4
142. E. Johansson, G. Steineck, L. Holmberg, J.-E. Johansson, T. Nyberg, M. Ruutu, and et al. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian prostate cancer group-4 randomised trial Lancet Oncol 12 9 2011 891 899
143. A. Bill-Axelson, L. Holmberg, M. Ruutu, H. Garmo, J.R. Stark, C. Busch, and et al. Radical prostatectomy versus watchful waiting in early prostate cancer N Engl J Med 364 18 2011 1708 1717
144. A. Bill-Axelson, L. Holmberg, M. Ruutu, M. Haggman, S.-O. Andersson, S. Bratell, and et al. Radical prostatectomy versus watchful waiting in early prostate cancer N Engl J Med 352 19 2005 1977 1984
145. A. Bill-Axelson, L. Holmberg, F. Filen, M. Ruutu, H. Garmo, C. Busch, and et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial J Natl Cancer Inst 100 16 2008 1144 1154
146. L. Holmberg, A. Bill-Axelson, G. Steineck, H. Garmo, J. Palmgren, E. Johansson, and et al. Results from the Scandinavian prostate cancer group trial number 4: a randomized controlled trial of radical prostatectomy versus watchful waiting J Natl Cancer Inst Monogr 45 2012 230 233
147. L. Holmberg, A. Bill-Axelson, H. Garmo, J. Palmgren, B.J. Norlen, H.O. Adami, and et al. Prognostic markers under watchful waiting and radical prostatectomy Hematol Oncol Clin North Am 20 4 2006 845 855
148. L. Holmberg, A. Bill-Axelson, F. Helgesen, J.O. Salo, P. Folmerz, M. Haggman, and et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer N Engl J Med 347 11 2002 781 789
149. A. Vickers, C. Bennette, G. Steineck, H.-O. Adami, J.-E. Johansson, A. Bill-Axelson, and et al. Individualized estimation of the benefit of radical prostatectomy from the Scandinavian prostate cancer group randomized trial Eur Urol 62 2 2012 204 209
150. E. Johansson, A. Bill-Axelson, L. Holmberg, E. Onelov, J.E. Johansson, and G. Steineck Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the randomized Scandinavian prostate cancer group study number 4 (SPCG-4) clinical trial Eur Urol 55 2 2009 422 432
151. G. Steineck, F. Helgesen, J. Adolfsson, P.W. Dickman, J.-E. Johansson, B.J. Norlen, and et al. Quality of life after radical prostatectomy or watchful waiting N Engl J Med 347 11 2002 790 796
152. A. Vickers, C. Savage, G. Steineck, H.O. Adami, J.E. Johansson, A. Bill-Axelson, and et al. Individualized estimation of the benefit of radical prostatectomy: data from SPCG4, the Scandinavian randomized trial of radical prostatectomy. Paper presented at Annual Meeting of the American Urological Association; 14-19 May 2011; Washington: USA J Urol 185 4 Suppl 1 2011 e716
153. A. Bill-Axelson, H. Garmo, L. Holmberg, J.E. Johansson, H.O. Adami, G. Steineck, and et al. Long-term distress after radical prostatectomy versus watchful waiting in prostate cancer: a longitudinal study from the Scandinavian Prostate Cancer Group-4 randomized clinical trial Eur Urol 64 6 2013 920 928
154. P.O. Madsen, P.H. Graversen, T.C. Gasser, and D.K. Corle Treatment of localized prostatic cancer: radical prostatectomy versus placebo; a 15-year follow-up Scand J Urol Nephrol Suppl 110 1988 95 100
155. P.H. Graversen, K.T. Nielsen, T.C. Gasser, D.K. Corle, and P.O. Madsen Radical prostatectomy versus expectant primary treatment in stages I and II prostatic cancer: a fifteen-year follow-up Urology 36 6 1990 493 498
156. P. Iversen, P.O. Madsen, and D.K. Corle Radical prostatectomy versus expectant treatment for early carcinoma of the prostate: twenty-three year follow-up of a prospective randomized study Scand J Urol Nephrol Suppl 172 1995 65 72
157. B.J. Norlen Swedish randomized trial of radical prostatectomy versus watchful waiting Can J Oncol 4 Suppl 1 1994 38 40
158. O. Sartor Implications of the prostate intervention versus observation trial (PIVOT) Asian J Androl 14 6 2012 803 804
159. T.J. Wilt The prostate cancer intervention versus observation trial: VA/NCI/AHRQ cooperative studies program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy with watchful waiting for men with clinically localized prostate cancer J Natl Cancer Inst Monogr 2012 45 2012 184 190
160. T.J. Wilt, M.K. Brawer, K.M. Jones, M.J. Barry, W.J. Aronson, S. Fox, and et al. Radical prostatectomy versus observation for localized prostate cancer.[Erratum appears in N Engl J Med. 2012 Aug 9;367(6):582] N Engl J Med 367 3 2012 203 213
161. T.D. Moon, M.K. Brawer, and T.J. Wilt Prostate Intervention Versus Observation Trial (PIVOT): a randomized trial comparing radical prostatectomy with palliative expectant management for treatment of clinically localized prostate cancer J Natl Cancer Inst Monogr 19 1995 69 71
162. T.J. Wilt, and M.K. Brawer The prostate cancer intervention versus observation trial: a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer J Urol 152 5 Pt 2 1994 1910 1914
163. T.J. Wilt, and M.K. Brawer Early intervention or expectant management for prostate cancer: the prostate cancer intervention versus observation trial (PIVOT); a randomized trial comparing radical prostatectomy with expectant management for the treatment of clinically localized prostate cancer Semin Urol 13 2 1995 130 136
164. T.J. Wilt, and M.K. Brawer The prostate cancer intervention versus observation trial (PIVOT): a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer Cancer 75 7 Suppl. 1995 1963 1968
165. T.J. Wilt, and M.K. Brawer The prostate cancer intervention versus observation trial (PIVOT) Oncology 11 8 1997 1133 1139 discussion 1139-40, 1143
166. T.J. Wilt, M.K. Brawer, M.J. Barry, K.M. Jones, Y. Kwon, J.R. Gingrich, and et al. The prostate cancer intervention versus observation trial:VA/NCI/AHRQ cooperative studies program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer Contemp Clin Trials 30 1 2009 81 87
167. M.J. Barry, G.L. Andriole, D.J. Culkin, S.H. Fox, K.M. Jones, M.H. Carlyle, and et al. Ascertaining cause of death among men in the Prostate Cancer Intervention Versus Observation Trial Clin Trials 10 6 2013 907 914